Elicit: Aflibercept's Mechanism in VEGFR Inhibition
Aflibercept's Mechanism in VEGFR Inhibition
How does aflibercept inhibit VEGF receptor (VEGFR-1/VEGFR-2) activation in retinal disease?
Aflibercept inhibits VEGFR-1 and VEGFR-2 activation in retinal disease by binding VEGF-A, VEGF-B, and PlGF with subpicomolar to picomolar affinity, forming 1:1 complexes that sequester these ligands and prevent their engagement with cognate receptors, while also occluding the heparin-binding site on VEGF to block alternative activation pathways.
Abstract
Aflibercept inhibits VEGFR-1 and VEGFR-2 activation in retinal disease primarily through high-affinity sequestration of VEGF family ligands, binding VEGF-A with subpicomolar affinity (KD = 0.490 pM) and blocking receptor activation with IC50 values of 15-26 pM. Unlike antibody-based therapies, aflibercept forms a 1:1 complex with VEGF dimers and uniquely occludes both the receptor-binding sites and heparin-binding site on VEGF165, preventing receptor engagement while exhibiting orders of magnitude faster association rates than bevacizumab or ranibizumab. This canonical mechanism translates to potent inhibition of downstream signaling including calcium mobilization, endothelial cell migration and proliferation, and restoration of barrier function across multiple retinal disease models.
Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Screening Criteria
- Retinal Disease Population: Involves patients with retinal diseases (diabetic retinopathy, age-related macular degeneration, etc.)?
- Aflibercept Intervention: Investigates aflibercept as the primary intervention?
- VEGF Receptor Mechanisms: Examines VEGF receptor activation or inhibition?
- Mechanistic Assessments: Includes molecular or pharmacological assessments?
- Study Design and Sample Size: Randomized controlled trial or observational study?
- Mechanistic Data Inclusion: Includes mechanistic data on VEGF receptor inhibition?
- Aflibercept-Specific Effects: Distinguishes aflibercept effects from other agents?
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study type | Disease model | Primary focus |
|---|---|---|---|---|
| Kanda et al., 2015 | Yes | Primary study | Human tissue (PDR), cell culture | Galectin-1 binding and neutralization |
| Deissler et al., 2014 | No | Primary study | Cell culture (bovine REC) | Barrier function and cellular effects |
| Pennock et al., 2014 | Yes | Primary study | Animal model (rabbit PVR) | PDGFRα-mediated mechanisms |
| Giurdanella et al., 2015 | No | Primary study | Cell culture (human pericytes) | Pericyte protection via PLA2/COX-2/VEGF-A pathway |
| Crespo-Garcia et al., 2017 | No | Primary study | Animal model (laser-induced CNV) | PlGF/VEGFR1 in immune cells |
| Cehofski et al., 2022 | Yes | Primary study | Animal model (porcine CRVO) | Proteome changes |
| MacDonald et al., 2016 | Yes | Primary study | Cell culture, human clinical trials | Binding stoichiometry and Fc effects |
| Sharma et al., 2024 | Yes | Primary study | Human samples, mouse CNV model | HIF-1α/ANGPTL4 pathway |
| Binding and neutralization, 2012 | Yes | Primary study | Cell culture (HUVEC), clinical trials | Binding kinetics and receptor activation |
| Lange et al., 2023 | Yes | Primary study | Animal model (rabbit retinal hyperpermeability) | ANG2 suppression |
Target Binding Properties
Aflibercept exhibited distinct binding characteristics across VEGF family ligands. The drug bound all isoforms of human VEGF-A with subpicomolar affinity (KD = 0.490 pM) and also demonstrated binding to human PlGF-2 and VEGF-B. The association rate for VEGF-A binding was orders of magnitude faster than that measured for bevacizumab and ranibizumab. Aflibercept’s binding features include a 1:1 stoichiometry with VEGF dimers, contrasting with the multimeric complexes formed by other therapies.
VEGFR Inhibition Mechanisms
Aflibercept inhibits both VEGFR1 and VEGFR2 activation through high-affinity ligand sequestration, blocking their activation pathways, demonstrating significant potency compared to other treatments.
Downstream Signaling Effects
Aflibercept’s VEGFR inhibition also produces critical effects on endothelial cell functions, restoring and preventing disturbances in barrier integrity, and inhibiting migration and proliferation driven by VEGF-stimulated pathways.
Effects on Retinal Cell Types
Quantitative Measures of Effects
| Cell Type | Effects | Quantitative measures |
|---|---|---|
| Retinal endothelial cells | Reduced migration and barrier disruption | IC50 for VEGFR1/R2 inhibition: 15-26 pM |
| Retinal pericytes | Improved viability, prevented damage | Viability assessed by MTT and Evans blue |
| RPE cells | Increased migration and proliferation | Increased cell viability |
| Mononuclear phagocytes | Reduced activated subretinal MPs, especially PlGF-expressing MPs | Correlation with reduced CNV leakage |
Functional Outcomes Across Retinal Disease Models
| Disease Model | Outcomes | Efficacy Measures |
|---|---|---|
| PDR (human tissue) | Suppressed galectin-1-induced VEGFR2 activation | VEGFR2 phosphorylation |
| Diabetic macular edema | Restored barrier function | Transendothelial resistance (TER) |
| PVR (rabbit) | Preserved retinal function | Electroretinogram assessment |
| CNV (mouse laser model) | Reduced activated MPs | Subretinal MP counts |
Synthesis: Canonical and Non-Canonical Mechanisms
Aflibercept's efficacy in retinal disease is attributed to both its direct inhibition of VEGFRs and non-canonical pathways involving interactions with other molecular targets, notably galectin-1 and PDGFRα. This multifaceted mechanism promotes further understanding of its therapeutic implications and potential resistance strategies.
References
- Atsuhiro Kanda, et al. (2015). Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Scientific Reports
- D. MacDonald, et al. (2016). Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab. Angiogenesis
- H. Deissler, et al. (2014). Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Experimental Eye Research
- C. Lange, et al. (2023). Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model. Translational Vision Science & Technology
- Deepti Sharma, et al. (2024). VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept. Proceedings of the National Academy of Sciences